CBG002

CBG002 is an autologous, armored BCMA-targeted CAR-T cell therapy engineered to constitutively express CD27, a costimulatory receptor. The addition of CD27 enhances T-cell proliferation and differentiation by binding its ligand CD70, resulting in improved persistence and cytotoxicity of the CAR-T cells. Preclinical studies demonstrated that CBG002 exhibits enhanced proliferation, greater cytotoxicity, and a higher proportion of memory T cells compared to conventional BCMA-CAR T cells. In animal models, it led to improved tumor control and prolonged survival in multiple myeloma xenograft mice. Clinically, phase I trials have shown that CBG002 is safe and effective for patients with relapsed or refractory multiple myeloma (RRMM), with an overall response rate of 81.8% and manageable adverse events[1][2][5].

Other names

CD27-Armored BCMA CAR T-cell TherapyCD-27-Armored BCMA CAR T-cell TherapyCD 27-Armored BCMA CAR T-cell TherapyCBG002 CAR-T Cell SuspensionCBG-002 CAR-T Cell SuspensionCBG 002 CAR-T Cell Suspension